Drugs / Curcuvail®
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06256926 Comparator | Jan → Nov 2021 | NAFLD1 | COD Research Private Ltd | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Curcuvail | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06256926 ↗ |
| Known as | Curcuvail 250 mg capsule | “Curcuvail® 250 mg capsule” NCT06256926 ↗ |
| Route | Oral | “Route of administration: Oral” NCT06256926 ↗ |